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Justin Shore*
Good morning, everyone. Thank you for coming.
It is a pleasure to have you here. My name is Justin
Shore. I am the president of the Health Law and
Justice Initiative, and along with the Health Law
& Policy Brief and the IHealth Law and Policy
Project, we are pleased to present our Founders
Day event, Drags, DNA and lou-Personalized
M/edicine in the 2 1st Century. We have three
amazing panels before you today. Our first panel
will be moderated by Professor Corrine Parver,
practitioner-in-residence and executive director
of our Health Law and Policy Project.
Corrine Parver*
Good morning, everyone. We have a great panel
this morning that I would like to introduce.
Our first speaker is Julie DeLoia, interim dean
of Georgetown University School of Nursing
& Health Studies. She joined the University in
August of 2007 as the associate dean of academic
affairs and associate professor in the Department
of Human Sciences in the School of Nursing and
Health Studies. Prior to that commitment, she
was instrumental in founding the University of
Pittsburgh's Ovarian Cancer Center and served as
the center's director ofresearch. She has published
more than forty-five peer reviewed articles, has
served as the principal investigator on two R01
grants of the National Institutes of Health, and is
a co-inventor of a patent for gene copy number
profiling. She holds a PhD in human genetics
from Johns Hopkins University and completed
a postdoctoral fellowship at the University of
Pennsylvania in developnmental genetics.
To Julie's right is Gail Javitt, who is counsel in
Sidley and Austin's Food and Drug Regulatory
Practice. She joined Sidley after seven years
at the Genetics and Public Policy Center in
Washington, DC as the law and policy director. In
that position, Gail was responsible for developing
policy options to guide the development and use
of reproductive technologies and also led an
initiative to provide oversight of genetic testing
quality. She was a Greenwall Fellow in Bioethics
and Health Policy at both Johns Hopkins and
Georgetows n Law Center and has worked
as a research scholar and adjunct professor
at both institutions. In addition to her Xork
accomplishments, she has vwritten on a variety
of science, regulatory, and legal topics, inchiding
direct-to-consumer marketing of genetic testing
and Food and Ding Administration (FDA)
regulation of biotechnology. She also is on the
editorial adsvisory committee of the Food and
Drug Lass Institute. She holds a bachelor ot arts
magna cum laude from Columbia College, a JD cum laude from
Harvard Law School, and an MPH from Johns Hopkins University.
Jo Gail's right is Sheila Walcoff, who is the founding principal and
health and science attorney of Goldbug Strategies, LIC. She offers
business strategy, federal legislative and regulatory advocacy, and
legal counsel related to personalized medicine and FDA-regulated
medical products. Previously, she was a partner in the international
law firm of McDermott Will & Emery. Her senior executive
government service includes counselor for science and public
health policy to the United States Department of Health and Human
Service and, particularly, to the secretary, Michael 0. Leavitt. She
was the associate commissioner for external affairs at the Food and
Drug Administration. As well, she was the health policy team leader
and senior health policy advisor on a 2007 presidential campaign.
She has worked on Capitol Hill as majority counsel to the U.S.
House of Representatives Armed Services Committee and has held
legal and policy positions at two trade associations. She graduated
from Georgetown University's Law Center.
Our final speaker this morning is Jeff Gibbs, counsel at Hyman,
Phelps & McNamara, a firm serving clients regulated primarily
by the Food and Drug Administration. He has represented health
care companies on FDA-related matters since 1984., advising
them on a wide variety of issues, including product approvals,
marketing clinical studies, and enforcement. Prior to working at
Hyman, Phelps served in the Chief Counsel's Office of the U.S.
Food and Drug Administration as an associate chief counsel for
enforcement. He is currently on the editorial advisory board of IVD
Technology and Good Clinical Practices and is a member of the
Human Subjects Research Board for George Mason University. He
serves as secretary and general counsel of the board of directors
of the Food and Drug Law Institute. He graduated from Princeton
University summa cum laude and the New York University School
of L aw with honors.
We are indeed privileged to have such a wonderful panel of experts
with us this morning. Personalized, or patient-tailored, medicine
uses new methods in molecular analysis to help manage a person's
disease or a predisposition towards a disease. The goal here is to
achieve optimal medical outcomes by helping physicians and their
patients select patient-specific disease management approaches
based on a person's genetic profile. Such approaches may include
genetic screening programs that more precisely diagnose diseases
and their subty pes or that help physicians select the type and dose
of medication best tailored for a certain group of patients. Data
on human genetic variation helps scientists to understand human
origins, susceptibility to illness, and genetic causes of disease.
But one of the more controversial elements of advancing technology
is the use of race and genetics to help create more specific types of
medicines that will help combat diseases and conditions that appear
to be more prevalent xwithin certain races or ethnic groups than
issue of how race and genetics have affected the development of
medicines, pharmacogenomics, and personalized medicine in the
United States. They will address legal and ethical issues relating
to research that relies on the use of genetic information and also
will examine significant issues facing the future of personalized
medicine that tailors patient clinical therapies based on the results
of genetic testing. With that very brief introduction, I would like to
call upon Julie DeLoia to present her remarks.
Remarks from Julie De oia***
Welcome everybody. Thank you for the invitation. It is always fun
to talk about personalized medicine. By way of background, I am
not a lawyer. I have been a lab rat for many years, and now I am a
passionate educator and administrator. So when I was in school at
Johns Hopkins working on my PhD, people started talking about
this concept of sequencing the entire human genome. You have to
understand, at the time, I was required to do sequencing and it would
take months, literally, working seven days a week to generate about
three hundred base pairs of sequence. People thought this concept
of sequencing three billion nucleotides in humans xvas anathema.
It was crazy. It was very much a stretch. A lot of my professors, a
couple of them with Nobel prizes, were worried that this was going
to trash all of funding for science as we know it. You might get the
opportunity later in life to look back at your professors and say,
"Hey, you were wrong about something." They were wrong. The
Human Genome Project got kicked off in 1990. The technology to
actually complete the project did not exist. The informatics systems
did not exist to hold the data, to look at the data, to analyze the
data, to retrieve the data. But lo and behold, although it had a fifteen
year timeline, this project was completed ahead of schedule and
under budget. like all federal projects generally are [laughs]. As a
result of the Genome Project, not only do we know exactly how
many genes we have in our genomes as humans, which was actually
much smaller than what my professors told me, but we also got to
the next step of being able to analyze very quickly and, now pretty
cost-effectively, the differences between any two individuals at the
genetic level. Againx, we did this at a relatively small cost and a very
short turnaround.
in others. There is concern that race- or gender-based treatments
could be used to legitimate discrimination. Our speakers today will
address the relevance of genetic information and will touch on the
Why do we care, except for folks like me who just sort of dig on this
stuff? Well we know that we vary biologically. If I had a bad cold
and I were to sneeze on this group of folks, some of you would get
a worse cold, some of you w ould get the same cold that I had, some
of you w ould get sniffles, and some of you would just be irritated
that I was rude. The underlying mechanism for that sort of biologic
variation is genetic variation. If we look at the old (Mendelian)
genetics-the classical stuff that I was taught-those diseases
had a lot of impact on the families that actually had that burden in
the family. But from a public health perspective, it wasn't a great
impact. Strokes, heart disease, cancer, and adverse drug reactions
are the diseases and health concerns that we really want to be able
to approach to figure out who is at risk for what.
So if we lived in Lake Wobegon where all the health care providers
were perfectly knowledgeable and all the patients were completely
compliant, we still wouldn't have perfect health. There are
reasons for that. One is that we don't know who is at risk for what
disease. So we do sort of a population approach. I turned forty; I
got a prescription to go get a mammogram. I turned fifty; I got a
prescription to get a colonoscopy. Did I need those? Probably not.
Did I do them? Probably not [laughs].
One of the barriers to better health is that we don't know who is
at risk for what. A second barrier is we don't have great tools to
diagnose diseases early. The earlier you can find a disease or a
disorder, the better you are at preventing the consequent progression
and morbidity or death. We are not the best at diagnosis. If you
know any pathologists, I apologize. But a lot of current technology
is used in the following diagnosis process: we get a chunk of tissue,
slice it up, stain it with a two-cent dye, and pass it on to some folks
who work in labs that smell really funny, who look at it and give you
an idea of what that is., We know for sure that when you treat those
patients., they don't all respond the same way. Undoubtedly, there
are different diseases that look alike under a microscope.
We talked a little bit, and we will talk a little bit more, about
pharmacogenomics, which is sort of the poster child of personalized
medicine. A layperson may say, "Golly, what is my prescription for,
if it is not the right drug and the right dose for me? I kind of thought
you knew what you were doing."
The last part of this is prognosis. We still have a hard time predicting
the outcome of any indisidual disease. So now we go back to the
Human Genome Project and what it has done for us. Well, it has
allowed us to look at genetic vairiation between groups and people.
So we can usc genetic variation now to look at w ho is at risk for what
disease. Something that bothers every woman once she reaches a
certain age is that niggling fear "Will I get breast cancer'?" One in
ten women ultimately will get breast cancer. The reality is most of
those women are postmenopausal. But once you get to a certain age,
you start thinkng about that. How do we determine risk? Well, it
used to be by looking at family history, svhich is still a great tool for
geneticists. You can't beat family history.
But now there is a test called Onco Lues that combines a person's
own history and adds in some genetic markers to come up with a
personal risk for breast cancer. Again, do I still need a mammogram
at age forty? Well, maybe I can get this test and say, "No, you can
wait until forty-five or so." But one of the problems that you have
with a predictive test, is that it is based on archived samples. So
researchers have thousands of samples, with the patient's history and
the women's breast cancer history. They know who got cancer and
who didn't. It is all looking backwards. The next step is difficult. It
requires taking this information and using it to manage patients who
don't yet have cancer and trying to guess who needs to be screened
and who does not. That is where the trickiness comes in because
care providers are nervous to change how they manage patients
based on a test that is not yet validated. Insurance companies aren't
going to want to pay for it. For example. imagine someone who
is forty-three and there is not a strong family history of disease,
but the genetic markers put that woman at a higher risk. Is the
insurance company going to pay for more aggressive screening for
you? Are they going to pay for an MRI? Are they going to pay for
prophylactic Tamoxifen? They are not willing to do that without the
data that says this is worth changing patient management.
With many of these new genetic tests, you eventually get to at that
point. As of today, there are dozens of diseases and disorders that
are undergoing genetic analysis. They are the common diseases that
all of us will interact with either personally or through our families.
So that is coming down the pike. We are not ready to take the next
step, I don't think, to say, "We are going to put this into clinical
practice."
Early detection of disease is another thing that really could improve
health significantly. I have been working in the cancer field with
ovarian cancer, a disease where the mortality is very high because
there is no good screening test. There is no good diagnostic test
other than surgery. And generally, women come in because they
have symptoms-either GI symptoms or reproductive symptoms.
This is a common scenario with many cancers. You don't know it is
there until it has progressed far enough to cause physical symptoms
and, consequently, is difficult to treat. The cancer is very far along,
and their life expectancy is quite short.
There is a test out from Exact Sciences to find one of those cancers
that often remain silent until it is far along: colon cancer. Out of
disclosure, I have stock in that company because I think they have
a cool idea. Basically, the concept of the test is simple. Your feces
coining through the canal pulls cells and DNA with it as it travels
through. The DNA is indicative of what is in the colon and the
rectum. So, by collecting feces that contains DNA, you can use
this test and hasve a way to look at genetic changes happening in
the colon. It is a test that looks pretty good. It svill detect about 85
percent of cancers and about 65 percent of precancerous lesions.
Now that is not as good as getting a colonoscopy, but the ieality
is, thc sast majority of people at agc fifty who get that piescription
neser use it. If everybody who should gct a colonoscopy did get
one. I think there would be something like a ten-year backlog. So,
is this genetic test as good as colonoscopy? No. But is it better than
nothing'? You bet. And it is something that people may be more apt
to use. In 2008, the American Cancer Society advised that people
use stool DNA to do colon cancer screening. The test is not yet
FDA-approved. They are hoping in 2012 it will be approved and
launched in 2013. That is a five-year lag time, which is significant.
Obviously, more accurate diagnosis is a big thing. We know that for
many cancers, the response rate is highly variable; some will respond
to therapy and some won't. Yet, the cancers look alike on the slides.
If we could analyze the gene expression profiles, which again, are
part of personalized medicine, and be able to separate what looks
like the same cancer into different groups, you can now either treat
people more specifically or say something much more difficult:
"I don't have anything to offer you." That is something that most
health care professionals really have a tough time saying. So most
health care professionals generally try with first line therapy, second
line therapy, third line therapy, and then palliative care. Trhe reality
is we probably put many patients through expensive therapy, with
many co-morbidities, unnecessarily. Perhaps these patients would
be better served by treatment with palliative care earlier because we
simply have nothing that is going to help them. Hopefully, not only
will we be able to spare some people from useless treatments, but by
having the genetic profile from their diseased tissues, we can start
designing therapies that are specific for the genetic alterations that
are happening more specifically in that disorder.
Pharmacogenomics is a big, big area. Some drugs are great. With a
beta-blocker, odds are it is going to work pretty well for you. There
is probably no need to do high-end genetic analysis of the disease.
But in my field, cancer, we are pretty bad at predicting who is going
to respond to what drugs. If you can now start looking at those
tumors specifically, you can use more tailored therapy. And I would
say living in DC, we are lucky. We are in an academic medical
center corridor. We have the NIH. People who get sick here will get
the best care in the country. Most academic centers now do some
sort of genetic profiling for most cancers. Those people who live in
areas removed from academic medical centers will not always have
that level of access. That is an inequity that is built into the system
that is going to be there for a while.
Another use of genetic information is in determining drug dosage.
One great example is in determining the dose for a drug called
Coumadin, which is a blood thinner. About a million people go
onto Coumadin every year. Coumadin is tricky because it has a very
small therapeutic window. loo much Coumadin, you could bleed
out. Too little Coumadin, you could clot up. A lot of folks end up
in the ER after they go onto Coumadin hecause the dose w as not
quite fight. Many people who are on Coumadin are elderly and
so returning to the health facility to get their blood clotting time
checked cevery wecek is diflicult. It is a stress. Lo and behold, there
is great data out there to say if I weigh you, get your BMI, and do
simple genetic testing on just txwo single genes, I can account for
about half of all the xvariation in response to this blood thinner. With
this information in hand. a peirson's specific dose can he narrowed
and negativ e outcomes reduced IThis day is coming; people are
(CMS) before reimbursement for the FDA-appro-ved genetic test for
Coumadin dosing is approved. The question now becomes, Is the
bar for using genomic information higher than what it is for actually
prescribing drugs?
The last topic I want to touch is prognosis. It would be very useful
to identify which patients have a higher likelihood of recurrence
for a disease. The first, and only FDA-approved kit for predicting
recurrence for breast cancer, MammaPrint, is now commonly used.
About 250,000 women a year will be diagnosed with stage I breast
cancer. A vast majority of them are not at high risk for disease
recurrence. Without this information about vho is going to have a
recurrence, you are going to treat everybody aggressively because
you want to be safe. So if you can now identify those women who
are going to have a higher chance of recurrence, you can treat them
aggressively. Alternatively, you no longer have to treat those women
at a lov risk for recurrence. Trhis could save money for the health
system. And it could save co-morbidities for the women.
That was a quick overview from the science side, which is obviously
very exciting for me having been in genetics for a few decades
novw. Our ultimate goal is to improve the health of the population.
Tremendous questions remain. Who is going to pay for these tests?
Who gets the data? Who gets to use the data? Does the entire
population have access to these tools? What is the psychological
impact? What is the counseling that goes along with genetic
testing? My hunch is that I will spend a good deal of my remaining
time educating both providers and patients on what this information
means and how you can use it. Thank you for your time.
Remarks from GailJavitt****
Good morning, everybody, and thank you. Dr. DeLoia was
actually a great background and segue to my topic for this panel,
direct-to-consumer (DTC) genetic testing. When we think about
personalized medicine, there is the personalized nature of genetics
that is individual to us, but there is also a personalized aspect to
access. You brought up very well that issue of access. The traditional
model of getting genetic testing, or any testing, is through your
doctor. But vhy is that? A new model has come up in about the
excited. It seems so rational to have this be the first test approved
to determine drug dosage. But unfortunately, more studies have
been requested from the Center for Medicare & Medicaid Services
last ten years, trying to offer genetic testing directly to consumers,
bypassing the health care provider. This model has caused a lot
of consternation; adulation: and all sorts of other adjectives, both
positive and negative. I want to give you a bit of a history about this
debate because, while DTC genetic testing is just a way of getting
a genetic test to consumers, it is also a good lens to look at some
of the larger issues around genetic testing, including issues of law,
ethics, and policy.
So you know it is big when Google gets involved, right? Because
ain't nothin' more personal than Google. So a couple of years ago,
Google announced that it xvas taking a small stake in a genetic
testing company, 23andMe, which promised to help consumers
understand and browse their own genetic information. And there
probably even could be an app for that-whatever that means. At
the time, there was already a growing interest and concern about
genetic testing, but certainly having Google involved and focused
on how we get your genome raised the profile. Indeed, in 2008, Time
voted the retail DNA test, meaning over-the-counter, as one of the
best inventions of 2008.
How did ve get here? Well, certainly as a result of the Human
Genome Project and all the data that it allowed access to, there has
been a sharp rise over the last ten to twenty years in the availability
of genetic testing. There are more than two thousand diseases for
which you can get a genetic test. Now the tests may tell you different
things. They may be very definitive: "You will get this." Or they
may be less definitive: "You may be at increased risk for this." But
certainly what we can mine out of our genome-although a small
fraction ofwhat is in our genome-is steadily growing. And genetic
tests run a wide spectrum. If you are thinking about having a child
or perhaps you are already pregnant, you can find out what genes
you might be carrying and, therefore, find out what your future child
might be at risk for. If you do it when you are already pregnant, it
is called prenatal testing. You can even test embryos as part of in
vitro fertilization to try to select embryos that are free from certain
genetic defects.
In Texas, there has been a big controversy regarding what to do with
bloodspots left over from newborn screening. Every newborn in the
United States gets between five and forty tests when they are born
to detect genetic diseases. The genetic disorders of interest are those
where early intervention could both increase survival and prevent
bad health outcomes. There are sexveral types of genetic tests: 1)
diagnostic testing. which uses DNA to diagnose or identify xwhat kind
of disease you currently have-nevvborn screening is limited to this
diseases in this category; 2) predictive testing. vvhich as discussed
by Dr. DeLoia, tests for your risk of diseases such as cancer; and 3)
pharmacogenetic testing, nhich tests for nhat drug vvill vvork or vsill
not svork foi a pcrson and in nhat dose. And then outside the health
care ensvironment, there is paternity testing, ancestiry testing, and
forensic testing, as we all knosw about from C SI.
What is DTC genetic testing? What is the gloss? Well, it is three
components. First, there is the "testing." We talked about all the
things you can get tested for. Second, it is "genetic," meaning it
uses some sort of DNA or DNA derivative. Third, it is "direct-to-
consumer," meaning you don't need to go to your doctor to get it.
So what is a genetic? There is no single definition, but basically
you are looking at DNA/RNA, chromosomes, or proteins that
are coded for by your DNA either to detect things that you might
have inherited or problems you might have acquired: for example,
through ensvironment exposure (e.g., chemicals, radiation) that
mutates (causes changes in) your DNA.
Under the traditional model of genetic testing, you go to your
doctor, wx ho does a thorough screen and might order a genetic test.
You might get referred to a genetic counselor or geneticist, who
decides what test you get and what information you receive. And
the results go back to your doctor. So there is somebody standing
between you and your genome.
How did we get to this DTC environment? We have now a much
better understanding of the role of genes in disease, the ability
to sequence the genome or perform genetic testing. The cost of
performing the tests has come way down, and there has been little
regulation. All of these factors have enabled companies to offer
genetic testing directly to consumers.
In some cases, there has just been direct advertising of the
availability of tests. But most frequently when we talk about DTC,
we mean direct access. Ilow does it work? A customer will go to
a website and order a test. You will get a sample collection kit,
usually something you spit in or rub on your check, like kind of a
toothbrush. or a dry bloodspot. You send that to a company, which
will conduct certain analyses on it and send you a report. What tests
can be offered? All sorts of tests. IThe rate limiting step in terms of
offering a test DTC is that you have to be able to test saliva or blood.
So, for example, you couldn't have a DTC a miocentesis (which
is an invasive procedure), which is a good thing, I'm sure. But
there has been a huge growth of companies that offer DTC testing
on everything from what kind of earwax do you have to serious
diseases or serious disease risks. In addition to discrete tests, there
are a couple of companies that offer to look broadly across your
genome for risks based on certain variations.
Why have some people touted this test as the greatest thing since
sliced bread? Well, it is about access. It is about deciding what test
you want, and what concerns you may have about going through
a health care proxvidcr intermediary. And the results can motixvate
you to make lifestyle changes. So. foi example. Fiancis Collins,
the Director of NIHI, tried this test and apparently said that after he
receixved his results. he got off his motorcy c and started exercising.
And others have claimed that the test motivated them to take that
next step to make improxvements to their health.
Why are we worried? Well, because of the limited oxversight thus far.
Some people also hav criaised conccrns about vvhcthcr thcsc tests are
accurate. Other questions aie also troubling: Aie consumeis gctting
svhat they think they arc getting? Hlosw do ne knosw the companies
offering the services know what they are doing? How do xwe know
that consumers understand the information and are appropriately
using it? And xsho else will get access to the information'?
The Goverment Accountability Office (GAO) has been looking
into these questions since 2006. A much more recent hearing raised
concerns about the claims that are being made and the accuracy of
the results, and a number of government entities have recommended
improvements in oversight. GAO raised concerns about the results
being misleading, medically unproven, ambiguous, and thus,
providing no medical information.
A number of publications in the scientific literature state that many of
the tests currently offered DTC may have potential, but are not ready
for primetime. The evidence for many of the gene-disease associations
and many of the claims that are being made are just not there yet,
according to these articles. At the same time, some of the tests that
the health care providers think aren't ready for primetime are already
being offered. So there is a concern about the science lagging behind
the access or the access preceding the science. And studies comparing
some of the different companies have discovered that the results from
different companies don't agree with each other, depending on how the
companies report the results and on unknown factors- because a lot
of the laboratory methods used to perform the testing are proprietary.
One article recommended that there needs to be more data, given that
there was 50 percent or less agreement in the predictions between to
different companies. Additionally, although there are many assertions
about what the public may do and what mistakes may be made, we
don't know a lot about how those people who are accessing these tests
are using the information, what they understand, whether they are
satisfied, and whether any harms have occurred because of the testing.
Ihere is a need for more empirical data to answer those questions.
Overall, the message from the scientific community has been that the
test is not quite ready for primetime.
Another level of concern is that not only might you access your
DNA, but others may seek to access it as well. Very little law is
in the way preventing your professors or others from testing your
DNA without your permission. So isn't there a law to prevent all
of this? It is a law school; it is a good question to ask. When you
break that down, what would you want to regulate? What entities
would you want to provide the regulation, and for what purpose?
Do you want to stop it entirely because this is a terrible idea or
regulate it to make sure there is truth in labeling? There are a whole
variety of policy objectives you might want to reach. There are a
number of players who could potentially help us reach them, but it
has bcen xveiry much a iregulatory xvork in progress. FDA has xveiry
kindly issued a notice last neck that thcy arc haxving a meeting ncxt
month to talk about hon FDA should regulate DTC genctic tests.
IThey haxve said, "We xwant to regulate them; xve are concerned about
them; xve think they are under our jurisdiction"-wvhich is a xvhole
topic in and of itself-"but xxe are really not sure hoxx to think about
the risks here." Is the risk of something that tells you hoxw to lose
weight better or the same as the risk of something that tells you, y ou
might get cancer or you need to change your medication? They have
asked for expert help in thinking through those issues because nwhile
And what can the states do? The states are a bit of a patchxwork-
got to love Federalism. Where some states say, "Look, if you want
to order any kind of lab test, except something really simple like a
pregnancy test, you've got to go through your doctor." Period. End
of story. Some states say, "Yes, consumers can order tests on their
own." And some states just haven't addressed it. In the era of the
Internet, what does it really mean to have states regulating this? It
may mean less than one -would like.
As I said, some government entities have recommended increasing
oversight not only of DTC, but of genetic testing more broadly.
Many of the concerns I have raised aren't really about the DTC-
ness, they are about underlying quality issues in genetic testing. As I
mentioned, DTC is just a way of getting a genetic test. Whether it is
DTC or through a provider, you want to have certain quality measures
met. As I mentioned, there are a number of policy approaches one
could take with pros and cons. So let me leave you with this: they
could range from "buyer beware"; to "you get what you pay for or
don't pay for"; to "take it with a grain of salt"; to "let's stop this
this is just not something we think that should be going directly. Just
like prescription drugs can be gotten only through a doctor because
we think that consumers need to go through a doctor to use them
safely, DTC is just not a good model for genetic testing." All those
options really are still on the table. As I said, FDA was kind enough
to announce a meeting. They have said they want to regulate. They
haven't said really how they intend to. It is part of FDA's broader
initiative to regulate laboratory testing. FDA has said that it expects
companies offering DTC genetic tests to comply with FDA's rules,
but the Agency has not actually said what those rules are. So we are
in a bit of a murky situation, I guess, is the best way to say it.
So we are still left with this question, and I an curious to hear what
you all think: Is direct-to-consumer genetic testing the best thing
since sliced bread or very scary'?
Thank you very much.
Remarks from Sheila Walcoff****
It is kind of hard to follow Gail. I would also have to say the murky
situation that we all tend to work in right now results in a great
employment opportunity for lawyers. The murkier it is, the more
the abstract "We should regulate it" has some merit, when you get
down to the nitty-gritty, it gets much more complicated, as I am sure
you have learned in all your laN school classes.
opportunities we have to tell the FDA what we think they should or
should not do and to get people to agree with us or not agree with us.
I thought I would start out by turning it back a little bit, not on direct-
to-consumer testing, but on those diagnostic tests that are physician-
ordered, those that you xwould have to go through your physician to
get. I thought I would start by just asking hoxw many of you know
somebody or are related to somebody that has had breast cancer? It is
usually a lot. And of those folks, how many know somebody who has
gone through chemotherapy? As you probably are aware from those
relationships, it is a pretty tough thing to go through. Something that
really surprised me when I started working in this area is for some
early-stage breast cancers, only four in one hundred women actually
benefit from chemotherapy. But right non, it is the standard of care.
Genomics is really changing that whole paradigm. Imagine that you, or
your mother, or your sister, or your aunt has early-stage breast cancer.
She can go to her doctor, and her doctor could order a test that can take
a look at the genetics of her actual tumor and then let her know and
advise her, as part of her decisions on treatment and how she is going
to go forward, what her risk of recurrence would be. Meaning, how
likely is it that that breast cancer is going to come back? Previously,
this was detenmined primarily on family history, age, and the size of the
tumor. But if you could actually look at the genomics of the tumor to
determine recurrence, then you could make a better-informed decision
on whether to have chemotherapy. In fact, genomics might even
identify women who would benefit the most from chemotherapy and
make sure that they get it. Perhaps they wouldn't have gotten it because
their tumor was very small or they are elderly. If we could reserve the
use of chemotherapy only for those at high risk for recurrence, we
could then enable those who are not at greatest risk for recurrence to
avoid the really toxic side effects of chemotherapy.
There are several such genomic tests. One of them has already been
mentioned this morning. There is sort of a burgeoning industry in
innovative diagnostics. Some tests use more complicated algorithms
that involve a lot more research and development, which are more
like producing a drug than a standard cholesterol test or other more
straightforard type of test that you would get in a lab. The rise in
the availability of such tests has developed a great area for lawyers
to determine how these tests are going to be regulated. It is not
just the direct-to-consumer tests that FDA is struggling with, as
Gail mentioned, it is all of these tests that are either developed and
performed nwithin a lab, which aie called laboratory dev eloped tests.
These tests are not shipped anynwhere in interstate commerce, which,
I'm suie, is something you haxe learned about because I spent all
kinds of time on interstate commerce nhen I nas in laxv school. And
there are kits that are produced for testing that are sold in interstate
commerce that are sent to these labs. Part of the challenge right now
for FDA is trying to determine wxhere it uses its regulatory authority,
what is its regulatory authority, and hon it uses its resources to
ensure that physicians and patients obtaining these tests are using
this information in a nay that they can be confident in. At that point
also, there is concern over whether an insurance company nwould
actually pay for the test, which is the whole reimbursement issue.
The key hurdles in my view for personalized medicine is hoxy
physician-ordered diagnostic tests will be regulated, how they will
be reimbursed, and how payers will pay for them so that they will
be available to you, your mother, your sister, and others who may
develop these types of very serious and life-threatening diseases.
What are the options for the FDA? What are the options for industry
in figuring outt nhat regulations it needs to follow to actually get their
tests on the market? Folks invest a lot of money in these tests and, of
course, they want a return on their investment. Right nov, it is really
a patchnwork quilt. Laboratory-developed tests are regulated by one
agency under the Clinical Laboratory Improvement Amendments
under the Center for Medicare & Medicaid Services and those tests
that are kits sold in interstate commerce are regulated by FDA under
the Food, Drug and Cosmetic Act (FDCA). Of course, FDA believes
it has authority to regulate all of these tests, an assumption that could
be a subject for a legal challenge. It hasn't been challenged at this
point. Ihat issue has been largely parked by a lot of stakeholders to try
to figure this out. What are the policy options going forward that are
reasonable, efficient, and do not completely stall all of the innovation
in this area (either because FDA is overwhelmed by its work, or the
rules are so unclear, or the bar is so high that companies won't invest
in making these more innovative tests)?
You can develop policy through a regulatory pathway, which
means looking at the current existing law and regulation to figure
out how you nmight fit the regulation of innovative diagnostic tests
into that law. Right now, FDA regulates diagnostic tests as medical
devices. A large group of stakeholders-----a lot of them that I work
with---- believe that diagnostic tests which produce information
that is used in treatment management are very different from your
understanding of a medical device like a knee implant or something
that actually touches or impacts your body. Ilow does FDA figure
that out? Should there be the same level of evidence required to
demonstrate that a medical device is safe and effective for its
intended use as there should be for diagnostic information that a
physician uses along with his or her training to determine xvhat your
treatment might be9 Is it different if that diagnostic test says, "You
have gene marker X, and you absolutely will not benefit from this
particular drug"-that's pharmacogenomics-or, "You have gene
markerY, and that means you absolutely would get a great benefit so
you should definitely use that." Some of the questions that the FDA
is constantly asking in these debates are, what if the test is nrong?
What if you have a false positive oi a false negative? And, hov often
can that be the case and you still viexv those tests as ieliable?
While the FDA and a lot of great people are struggling with those
questions, there is another option, not just a regulatory approach
y on could take. We arc here in Washington. You could take a
legislatixve approach. You can march up to C apitol Hill. bringing all
of youi stakeholders and explain to Congiess xvhy we should haxe
a ncxv law that icgulatcs diagnostic tests differently than medical
dcxvices. This Ianw peihaps sets up a ncxv framework based on the
risk of information rather than the risk of a thing itself that might
touch your body. But if you take the legislative approach, you have
to create new definitions. What is a diagnostic test? What does
this include? What doesn't it include? What are the factors for
determining risk? Is it that it is a one-to-one relationship-if you
have this marker you get this drug? That is the most risky versus
a test that provides information about whether you might be at a
higher risk for recurrence of breast cancer, or you may not. It is
more of an adjunctive use that the doctor would use along with other
information. What if people think it is really no risk at all? We have
been doing this test for ten years, and we really understand how it
works and what the results mean. Maybe FDA shouldn't step into
that because whenever a regulatory agency steps in, that usually
means increased cost and increased time to market, which factor
into how fast personalized medicine will develop.
What are the answers? I think there really aren't any right now. It has
really proven to be one of the most fascinating areas in which I have
ever practiced. It is why I actually left my law firm and formed this
company called Goldbug. I am sure you have all been wondering
what is Goldbug vhile you have been sitting there. Why would I
leave a great three-name law firm to do that? It really is because of
my love for personalized medicine. It doesn't refer to a virus. I had
somebody ask me that once, "Is Goldbug like a unique virus?" It is
really based on a children's book swhere you find the gold bug. You
all are probably either too old or too young to know this book, if you
don't have little kids. But there is a book by Richard Scarry called,
"Cars and Trucks and Things That Go," which has crammed onto
page illustrations of all these different vehicles, like the toothpaste
car and the mustard car. And there is a storyline through it. On every
page, there is a gold bug. I vas actually reading the book to my son
one night. I looked at a page depicting a massive crazy car crash and
thought, "That is just like Washington. That is our policymaking
process, our legislative-making process." There are all of these crazy
ideas and things going in different directions, but at some point it
makes sense, and at some point there is an answer. That is really
how I feel about personalized medicine. I hope you all continue on
with this and help me. We'll all need associates--sooner rather than
later, probably as we are going forward.
Remarks from Jeff Gibbs******
My focus is on FDA regulation, which is a little bit different from,
but complementary to, the other three perspectives. What I want
to do, in the someswhat limited time that we have, is just quickly
talk about ten different points. It is kind of a "Dave Letterman Top
Ten List," although not necessarily in ranked order. But here are ten
points that I think are worth considering.
First, it is clear that diagnostics are fundamental to the advancement
in medicine, such as towards what swe heard about with breast
cancer medicine. It is perhaps a 4 percent response rate. I just read a
book that talked about leeches. Two hundred years ago leeches were
the thing. They had been the thing for centuries, and sometimes
leeches worked. In fact, FDA has cleared leeches for marketing
for medical purposes. They have cleared leeches for use, proving
that they really do work in certain conditions. However, most of
the time they don't work. The problem nwith leeches was that they
vere applied in inappropriate conditions, so most people did not
get better. It is not that different now from chemotherapy. So, as
we sit here looking back smugly at the doctors and physicians who
used leeches two hundred years ago, people fifty years from now are
going to be looking at us and saying, "We can't believe that doctors
in 2011 subjected patients to the rigor of chemotherapy with all the
pain and discomfort and risk when it was completely inappropriate
for 95 percent of patients." Thus, personalized medicine is going to
be essential.
Second, there are many factors that influence the availability of
personalized medicine. We have heard of some of them: technology,
reimbursement, science, and patents. But there are huge intellectual
property issues. Those of you who are on the patent side, it is a
burgeoning field. There is a case going up now about accountability
of genes. But there are also regulatory concerns. Gail and Sheila
talked quite eloquently about some of the regulatory challenges,
particularly on the FDA side. The regulatory issue has to be
addressed. It is a major stumbling block right now. What will the
regulatory regime look like? We need greater clarity. People need
better predictability.
Third, the basic FDA regulatory framework does not work terribly
well for diagnostics, particularly the new diagnostics. And there
are a lot of reasons for that. But the basic problem is that the law
xvas written in 1976, and it was constructed for different kinds of
products and at a different time to address different issues. One
of the major pathsways to getting products on the market through
FDA is called the 510(k), referring to section 510(k) of the [Federal
Food, Drug, and Cosmetic] Act. In order to get a 5 10(k) you need
to show substantial equivalence to what is called a predicate device.
The nevs products that are coining out in personalized medicine
and diagnostics don't have predicates. That is wshat makes them
valuable. They are different. Net if you are fled to predicates, you
hasve a bump in the system. The other approach or the other route
to market is called a premarket approsval application, which is vecry
costly and very time-consuming. There are a lot of reasons wshy
those xvould be bairriers to innosvation, and yet the statute does not
really handle the situation xvell.
Another category is called de novo reclassification, svhieh allows
companies to reclassify products if there is no predicate device. It is
on the books. It has been used about four times a year since it was
adopted-about tvso diagnostic devices a year. So it exists, but it is
not really viable. That is just one of the reasons why a legislative fix
is needed to address what is really a fundamental structural flaw in
the law.
Fourth. in addition to the law itself, there are problems with FDA's
regulations. FDA developed regulations without thinking about
diagnostics. For example, if you get your product cleared by a
510(k) and you make a change, you have to submit a new 510(k) if
that change could significantly affect the product. With these new
diagnostics, they are always making changes. There are always new
markers and better algorithms that are being developed. You think
about what you want with these diagnostics, and what you want
is something that keeps up with knowledge, evolves with the state
of the art and is flexible. You don't want something that is cast in
stone and has to stay the way it is based on the knowledge at the
time when it was cleared or approved by FDA. But that is the way
it works under the current system. Unless there is a way to handle
new knowledge, new markers, and new algorithms, and better ways
to use the diagnostics, we are going to get products that are cleared
that are going to be obsolete almost instantly. That is another major
flaw with the regulatory structure right now.
Fifth, companies need to do a better job. There are problems with
the law,. FDA's regulations, and with the way companies handle
their diagnostics. And by companies, here, I am talking specifically
about diagnostic companies. If a company has got a novel product
and it can go in to meet with FDA and ask, "What should we do?
How do you like our protocol? How do you like our claims?" And
companies have these meetings, and then they get FDA's feedback,
and then they ignore it. Or they will get the study design drafted,
get it reviewed by FDA, and not follow FDA's advice. Or they will
submit an application to FDA which is poorly crafted, and FDA has
a hard time making sense of it. Some of the burden lies on industry.
And industry is going to have to do a better job in presenting data
and doing good science. When you are talking about cutting-edge
products that are going to be the basis for making decisions on
whether you have surgery or administer chemotherapy, companies
have to do a much more rigorous job. We are not talking about
cholesterol tests anymore, and the standards that applied for
cholesterol and other basic blood chemistry don't work.
Sixth, drug companies have to do a better job understanding
diagnostics. Some of the most important applications that we
have relate to drugs. If the drug companies don't kinovv hon to
use diagnostics, then they are going to find that their nay to FDA
approval is going to be hampered. There is a nevv report about how
the percentage of drugs getting through the process and succeeding
has dropped ev en more, and part of the problem is that they are
not taking adv antage of the diagnostic tools that vvould improv e the
success of drug companies.
Sevent, one of the things that is abundantly clear to me having
worked both wiith diagnostic companies and drug companies is
that drug companies don't understand diagnostics at all. It is just
astonishing how they will be far along in their process and then start
thinking, maybe we ought to have a diagnostic. They have already
spent $100 million dollars, and then they start thinking about,
maybe we should find some way to identify the patients who are
going to respond. Some of these cancer drugs have a ten percent
response rate. It is not random. There are factors that lead to people
responding. Why aren't the companies doing a better job analyzing
and trying to figure out who are those 10 percent and developing a
companion diagnostic to go along with it? That is an area that needs
a lot of improvement.
Part of the problem there on number seven, it is not just the
drug company's fault. FDA has been working on a guideline for
companion diagnostics for years. It is still not out.' Everybody is in
the dark. We have heard the nord "murky" here. This is murky. It is
another murky situation, and it vould be much easier for diagnostic
companies and drug companies if there were clear guidelines on
how to handle these companion diagnostics.
Eighth, FDA needs to take a different way at hoxy it looks at risk for
diagnostics. These are not the implants; they are not cardiovascular
products; they are not defibrillators. Risk needs to be assessed
differently. It is a separate topic. You could have a vhole seminar-a
two-day seminar-on risk in diagnostics and how do you calculate
it, how do you assess it. But a fundamental problem with the whole
process right now is how FDA evaluates risk with diagnostics, and
is the level being set too high, and what does that do for accessibility
and availability?
Ninth, I think it is useful to have a presumption in favor of more
information rather than less. That notion permeates the U.S. system
from the First Amendment onward, and yet FDA in general takes a
much more restrictive vievw. And if you think about diagnostic tests,
perhaps they don't tell you the answer, but they may be additive.
The appropriate question, I think, is not to ask, "Do they answer all
questions?" But the question should be, "Compared to the standard
of care right now, do they provide useful information that will
help make better decision-making?" If doctors are going to have
a better idea of nhether this is a patient who responds to leeches
or chemotherapy, then it is a useful tool. It may not tell everybody
who is going to respond and not respond, but if you can double
the success rate, that is certainly an improvement. So the role of
information and incremental benefits in information, I think, needs
to be assessed better.
And then tenth, FDA has to use its resources more efficiently. We
have hcaid about FDA looking at lab-dcxveloped tests. We could
debate nbether FDA has thc legal authoirity, but I don't think thcre is
much debate that FDA has put a lot of time, effort, and money into
it. Given the president's budget and given vvhat Congress is doing
with the budget, the idea that FDA should expand its jurisdiction to
take on huge nevv endeavors is something that is highly debatable,
But even aside from that, FDA needs to be efficient iwith its existing
resources. FDA, vvhen it has these meetings nwit companies and
develops guidelines, has to be prepared, has to give good guidance,
has to come out with guidelines to provide meaningful information
that will help guide the regulatory process. There are a lot of things
that could be done right now so that FDA gets more with existing
resources. I think the FDA has to think long and hard about taking
on any more responsibilities given the contraction or liimits in
funding that will be available.
I could easily have expanded this to twenty or fifty or one hundred
points, but these are ten points that help, from my perspective, frame
some of the key issues involving FDA regulation of diagnostic
devices.
QU ETINS )ANDANSWERS
QUESTION: For the panel overall, in terms of "it is a murky
situation," how do we actually push this regulation forward? Is this
where you see, for instance, public-private partnerships coming in,
FDA's critical path, those sorts of situations? Is that where you see
maybe the best chance for regulation, or do we actually think that
there is a legislative fix that could be coming soon? Where do you
see this actually going in the next few years?
SHEILA WALCOFF: As Jeff and others have mentioned, there
has been a lot of work at the FDA. This has been going on for a long
time. In fact, I was actually at FDA and at HHS when this started
four or five years ago in earnest with respect to these more innovative
diagnostic tests and how they might expand to laboratory-developed
tests. As I said, there are two pathNays, regulatory and legislative. I
think there is emerging a more realistic and viable legislative fix. It
is a complicated effort to go for a legislative fix. I was skeptical at
first, years ago, because I thought, "Well, we can continue to work
with the agency." And they certainly are open-and I think even
more open now than they have been in previous years-to getting
stakeholder input because it is difficult. It is hard. They are stuck
with a law, a statute and regulations, that as others have said, doesn't
really fit for what these new innovated products are. And they are
trying to make it fit, and it is ill-suited, and we are trying to figure
out how do we establish appropriate standards for regulation so that
companies know what they need to do and that the agency knows
how it needs to respond.
Because there is this kind of stalemate and continued murkiness
and inability to get an answer really out that is going to work for the
industry and work for the agency, there has been a pretty significant
effort to get legislation-one member and a couple members, in
particular, with Senator Hatch from Utah emerging as a leader in
personalized medicine. He has been very interested in this area
for a nnmber of years, and he is working on a draft bill that is
fairly substantial. It is very technical. It creatcs a separate medical
pioduct that is iegulated by FDA called in v itio diagnostic pioduct.
It intcnds to be technology neutral and business model neutial,
meaning it wouldn't matter if it was a kit in interstate commerce
versus a laboratory-developed test, trying to bring that regulation
together in a more unified fashion. Some people like to say. "ILevel
the playing field?' hut it is definitely more complicated than that. It
is great, and there has been a lot of vvork from a lot of stakeholders
that have gone into this proposed legislation. But it is one member,
and it is a bi-partisan issue certainly, bicameral issue, and there is
a lot of work going into that right now, but there is still a big road.
As I like to describe it to my clients, it is really a marathon. It is not
a sprint. Otherwise, you sprint and you become exhausted. Actually,
you become manic-depressive over it because one day you think
everybody is in the same lane, and all the stakeholders are going
in the same direction. But the next day you find out that this major
group has just peeled off, and now they are talking to some other
member and doing something completely different. So getting all
that to work together, I think there is a great opportunity in the next
two years. With the FDA, there is a structure in place for approval
of medical products that utilizes user fees and that has to be re-
authorized .every so many years. I think it is every four years. And
that is coming up in 2012. So what we say is that provides a viable
legislative vehicle, a way to actually get this through. There are
a lot of steps in that process. I think we are closer than we have
been in the past because we are really starting to understand what
does personalized medicine mean, what do we really need in this
industry? Legislation previously has called for an IOM study. Well
that is very good; it is something you can get through. it sounds
great. The IOM is very distinguished, but then what do you do?
Then you are still stuck with this statute that doesn't really work. So
I guess the short answer is, "Yes there is a lot of work going on in
the legislative side." It is very exciting for a lot of people, but it is
also very frustrating. I think it is not something that is going to be
resolved quickly.
GAIL JAVITT: And, actually, just an historical note to add on;
Professor Grossman will correct me if I am wrong. If you look
at almost every legislative change, including the creation of the
FDC Act itself, was driven by crisis, disaster, and death. So-
Thalidomide, strengthening of the act, the Dalkon Shield, food
safety. You don't have that here, which is a good thing. So you need
people to coalesce around other big ticket things. like improvement
of health and impeding of business development, but it is harder to
get legislation through when you don't have that. I think the history
of the FD&C Act bears that out.
JEFF GIBBS: That is absolutely true. Historically, it has been
largely driven by significant problems. But this could rise to a level
soon, not of a health care crisis like Thalidomide or Dalkon Shield,
but of a major issue. I don't know about the legislative prospects.
I defer to Sheila on that, but I do know that we really can't wait
for legislation to be adopted for companies that are dealing with
FDA right novs Thcre is an ongoing piroblem. I vvork vsith a lot of
companies that are struggling right now. If legislation is enacted,
say in 2012 vvhen the user fees come up, there aie going to be a
lot of issues in the meantime. But also once it is done, ev ery piece
of legislation runs into implementation questions, rule-making,
enforcement, guidance. And so legislation might be a great start. It
could address some of the major issues that we have, some of the
fiavvs that are structural. but it is not going to be the whole solution. I
thin that to your quesrion, there really does need to be involvement
with stakeholders of all sorts-probably a lnndamental rethinking
of how to handle this.
To use the tired phrase of "paradigm shift," the vay that FDA and
companies are working right now is just not terribly efficient. Some
fixes can be done by just rethinking, What is the role of diagnostics?
What do we expect from them? fHow do we want to view them?
What should the criteria be? And some of that could be done right
now without legislation, but there are very different perspectives on
it as well, and that is going to require input from a lot of different
people to think what should we do with diagnostics. What standards
do we want to apply? Those are very important kinds of questions
that need to be addressed very rapidly.
CORRINE PARVER: Perhaps cost, though, can push the envelope
a little bit. I was astonished to learn the statistic that you quoted
that only 4 percent of patients actually improve with chemotherapy
when it is the standard of care for all patients who have breast
cancer to have chemotherapy or radiation. With a focus on cost
containment and both houses of Congress looking to ways to try to
decrease spending, if you look just to the Medicare population and
the incidence of breast cancer in people of sixty-five years of age
or older, there is a tremendous amount of costs savings there. Isn't
something like that a rationale?
JEFF GIBBS: It is a real paradox because right now you think
of some of the expensive drugs-the chemotherapy drugs that cost
$50,000 to $100,000 a year and yet benefit a relatively small set
of patients. If you could come up with a diagnostic test that would
identify people who are much more likely, you could save a lot of
money. But when it comes to reimbursement of diagnostic tests,
there are very poor payment procedures. You talked about Coumadin
as an example. We thought that the Coumadin diagnostic was
going to be a great role model better titration, better outcomes.
But Coumadin genetic testing has been very poorly adopted for a
variety of reasons including the lack of reimbursement. So yes, you
would think that people would be looking at this and saying it is
cost-effective, but so far that really hasn't happened to the extent
that one would have expected.
JULIE DELOIA: This is also through the medical provider's
psychological view. It is really tough if you have a forty-year old
woman with a couple kids who wants chemotherapy and you say,
"You have a pretty good chance of not getting recurrence," and she
wants the chemo just because she has a lot of life ahead of her. That
is a tough call for a provider to say, "I am not going to recommend
that this gets reimbursed." I don't see that happening for a long time
unless the validation studies are much cleaner.
SHEILA WALCOFF: I xvould just add what is interesting is the
standaird of care in some instances is ireally mosving beyond this whole
regulatory conundirum. You hasve medical societies recommending
certain tests that have been on the market for awhile that may or
may not have been subject to F DA approval-not because they have
axvoided it, but because they heliexe it is not required of them to be
legally marketed. You have a situation where the cancer societies are
telling physicians, "'This test is recommended in these instances"
and then y on wxill hear about it because of course it is the Internet age
and you go to your doctor and you say, "I xvould like this test. I want
to know if I am at risk for recurrence and if I really can have some
more information to make my decision about chemotherapy one
that is not easier but will give me greater confidence-some amount
of greater confidence. It may not be 100 percent, but it is something
more than nothing or where we are now.
And then the reimbursement challenge of that is some payers are not
paying for it. What that means is you could ask for that test and your
doctor could order a test and you can get the test, but you would
have to pay for it yourself because your insurance company will not
pay for it. That is also a struggle because that is not consistent across
third-party payers. Medicare might pay for it, but if you are in the
military and you are serving our country, TRICARE may not pay for
it. They have different standards to evaluate whether they are going
to pay for something or not and not even mentioning the private
insurance industry. So all of these things are forming together to
make this more of a crisis of a different market situation-a crisis
of a different kind.
JEFF GIBBS: I'm glad you mentioned TRICARE. It is a really
interesting case study. A few years ago FDA approved a Pfizer drug
for lIV And in the label it said that there should be a certain kind
of test that was done in a laboratory, and so it is in the label of the
FDA-approved drug, and IRICARE xvon't cover the test. So here
on the one hand you have FDA saying you have to do this testing in
order to identify the appropriate patient population, and TRICARE
saying we're not going to cover it.
JULIE DELOIA: One other comnment-will we get to a point
where if the insurance companies reimburse for diagnostic tests,
then you as a patient are obligated to go down that path? So, the
insurance company pays $3,000 for aunkatype, and the patient says
I am low risk for recurrence but I still want the chemo because I am
worried. And the insurance company says. "Okay, we'll pay for the
diagnostic-the $3,000 test but we are not paying you $50,000 for
the chemo." That is another caveat.
QUESTION: My question deals with the government's 180 in
Myriad deciding now that the Justice Department doesn't want to
support this idea of patenting human genome therapies, how does
that muddy the waters in terms of scaring off investors and making
it harder for these diagnostic companies to succeed?
SHEILA WALCOFF: I think for those of us in the audience
who don't know what Myriad is. Myriad is a company that does
genetic testing for markers in breast cancer. It actually is a very
complicated, very emotional issue with anyone you talk about in
terms of patenting because vvhat are y ou really patenting. I'm not
an IP (intellectual property) expert. btit wxith respect to the broader
qtiestion of hoxv does that impact investment and innovation, it
absolutely does. I thin most companies are waiting to see how
that ultimately resolves itself, most likely at the Supreme Court
lexvel. But if you are not able to protect your mv estment in your
product, in your intellectual piroperty, you are not going to make
that insvestment. I think that does stifle innovation. There is a lot
of debate about xvhether you need this particulai type of patent
or whether the other kinds of patents will be able to protect your
investment. As we move more into these more advanced diagnostic
tests, it does require a greater level of investment. Some of these
breast cancer tests we have talked about today have been upwards
of $50 million in the investment in the data to demonstrate that the
tests actually are supported by actual clinical data.
JEFF GIBBS: I think that the government's position might have
been more of 120 degrees because they didn't completely flip but
they took an intermediate approach, confusing everybody. That
was completely unexpected. But I think the bigger point and a key
aspect here is this uncertainty. Whether it is the Myriad decision
or the patent thicket, as it is called, where there are lots of patents,
and someone who wants to do a multiple sequence test has to
try to negotiate twenty, thirty, forty patents or whether it is FDA
uncertainty over a laboratory-developed test or the reimbursement,
all of those have an effect on innovation.
I have talked to venture capitalists and people in companies. Every
time that there is a change like this, it does have a chilling effect in
that the lack of certainty as to what is going to happen is a negative.
Now everybody investigating this knoxs that you can't have
complete certainty. That is not going to happen. That is unattainable.
But the high level of uncertainty that we have is having a deterrent
effect whether it is the Myriad decision or the FDA regulation of
laboratory-developed tests or reimbursement debates.
SHEILA VALCOFF: I xvould just add-vve talk about patent
thickets. There are ways to get through patent thickets and everybody
probably is holding one. There are definitely legal mechanisms
to get to a place of greater certainty, if we can just move past this
frustrating point we are in now.
CORRINE PARVER: Please join me in thanking our first panel.
